GLP-1 Agonists are already approved for weight loss in individuals without diabetes, and ongoing studies suggest that GLP-1 therapies may have broader applications in treating conditions like metabolic syndrome, fatty liver disease, and cardiovascular health
Oprea AD, Umpierrez GE, Sweitzer B, Hepner DL (2024) Perioperative management of patients taking glucagon-like peptide-1 receptor agonists: applying evidence to clinical practice
Cagrilintide peptide is studied in laboratory environments for its interaction with amylin receptor pathways and peptide-mediated signaling systems
In other words, people sought me out and new doors opened
What to Expect in Practice Its a structured, patient-centered experiencenot guesswork
doi: 10.1194/jlr.R036012 41